STAT3 and lung cancer: Despite the existence of numerous STAT3 inhibitors, none of them have achieved FDA approval for use in clinical trials for lung cancer, indicating that inhibiting STAT3 alone may not be sufficient to eradicate cancer cells (Huang et al., 2016).